<DOC>
	<DOCNO>NCT00303524</DOCNO>
	<brief_summary>The primary purpose study establish 10.8 mg dose ZOLADEX give 3 monthly non-inferior 3.6 mg dose ZOLADEX give monthly term oestradiol suppression patient oestrogen receptor positive early breast cancer .</brief_summary>
	<brief_title>Comparative Study Oestradiol Suppression : Zoladex 10.8mg/3 Month vs. 3.6mg/Month ER +ve EBC Pre-menopausal Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Premenopausal woman age 20 year histological/cytologicallyconfirmed ER +ve breast cancer undergone radical surgery WHO performance status 0,1 2 . Evidence metastatic disease , previous bilateral oophorectomy radiotherapy ovary , previous chemotherapy , breast surgery complete 12 week start trial treatment , previous neoadjuvant/adjuvant hormonal breast cancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>